Published in PLoS Med on February 03, 2009
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst (2014) 2.06
A network module-based method for identifying cancer prognostic signatures. Genome Biol (2012) 1.61
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One (2010) 1.58
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst (2014) 1.58
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Microarray analysis of RNA extracted from formalin-fixed, paraffin-embedded and matched fresh-frozen ovarian adenocarcinomas. BMC Med Genomics (2009) 1.47
PathScan: a tool for discerning mutational significance in groups of putative cancer genes. Bioinformatics (2011) 1.46
curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford) (2013) 1.40
Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment. PLoS Comput Biol (2013) 1.34
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One (2012) 1.31
PROGgene: gene expression based survival analysis web application for multiple cancers. J Clin Bioinforma (2013) 1.28
The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med (2011) 1.16
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res (2011) 1.15
Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. PLoS One (2011) 1.09
Pathway-based classification of cancer subtypes. Biol Direct (2012) 1.05
A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS One (2011) 1.05
E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer (2010) 1.02
Synergetic regulatory networks mediated by oncogene-driven microRNAs and transcription factors in serous ovarian cancer. Mol Biosyst (2013) 0.99
Sample-level enrichment analysis unravels shared stress phenotypes among multiple cancer types. Genome Med (2012) 0.96
Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer (2010) 0.95
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Med (2015) 0.94
Pathway index models for construction of patient-specific risk profiles. Stat Med (2012) 0.93
Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis. PLoS One (2013) 0.92
A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers. Mol Cell Proteomics (2012) 0.92
A comparative study on gene-set analysis methods for assessing differential expression associated with the survival phenotype. BMC Bioinformatics (2011) 0.89
Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics (2014) 0.89
Semi-supervised learning improves gene expression-based prediction of cancer recurrence. Bioinformatics (2011) 0.88
Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype. PLoS One (2012) 0.88
Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis. PLoS One (2016) 0.87
Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer. Br J Cancer (2014) 0.85
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer (2015) 0.85
Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med (2009) 0.84
A computational profiling of changes in gene expression and transcription factors induced by vFLIP K13 in primary effusion lymphoma. PLoS One (2012) 0.83
The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak. Bioorg Med Chem Lett (2014) 0.82
High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One (2013) 0.82
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets. Mol Cancer (2014) 0.81
Genome-wide modulation of gene transcription in ovarian carcinoma cells by a new mithramycin analogue. PLoS One (2014) 0.81
Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. J Proteome Res (2015) 0.81
In Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer. BMC Syst Biol (2011) 0.80
Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci Rep (2015) 0.80
Integration of zebrafish fin regeneration genes with expression data of human tumors in silico uncovers potential novel melanoma markers. Oncotarget (2016) 0.75
Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer. Genes Cancer (2015) 0.75
A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. Sci Rep (2016) 0.75
Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer. Br J Cancer (2016) 0.75
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin (2014) 0.75
Knockdown of TMEM45A inhibits the proliferation, migration and invasion of glioma cells. Int J Clin Exp Pathol (2015) 0.75
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med (2017) 0.75
Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer. Microarrays (Basel) (2015) 0.75
The modularity and dynamicity of miRNA-mRNA interactions in high-grade serous ovarian carcinomas and the prognostic implication. Comput Biol Chem (2016) 0.75
Aberrant Promoter Methylation at CpG Cytosines Induce the Upregulation of the E2F5 Gene in Breast Cancer. J Breast Cancer (2016) 0.75
Molecular genetics complexity impeding research progress in breast and ovarian cancers. Mol Clin Oncol (2017) 0.75
Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets. BMC Genomics (2017) 0.75
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res (2006) 44.35
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci U S A (2000) 18.42
Cancer of the ovary. N Engl J Med (2004) 11.21
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol (2004) 7.68
Fundamentals of experimental design for cDNA microarrays. Nat Genet (2002) 7.49
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Reliability and reproducibility issues in DNA microarray measurements. Trends Genet (2005) 6.79
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68
Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res (2004) 4.33
The JAK/STAT signaling pathway. J Cell Sci (2004) 4.23
beta-catenin signaling and cancer. Bioessays (1999) 4.16
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Getting the noise out of gene arrays. Science (2004) 3.91
Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol (2005) 3.82
A paradigm for class prediction using gene expression profiles. J Comput Biol (2002) 3.64
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell (2004) 3.30
Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol (2004) 2.91
TRED: a Transcriptional Regulatory Element Database and a platform for in silico gene regulation studies. Nucleic Acids Res (2005) 2.73
Molecular profiling of platinum resistant ovarian cancer. Int J Cancer (2006) 2.37
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med (1997) 2.33
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. J Clin Oncol (2008) 1.96
Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res (2007) 1.89
BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol (1998) 1.80
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene (2006) 1.78
Design considerations for efficient and effective microarray studies. Biometrics (2003) 1.77
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood (2006) 1.71
Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol (2005) 1.64
Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol (2007) 1.61
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer (2006) 1.55
Analysis of large-scale gene expression data. Brief Bioinform (2001) 1.41
Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res (2007) 1.40
The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. Br J Cancer (1999) 1.25
Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J Biol Chem (1991) 1.18
BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A (1996) 1.13
Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. Br J Cancer (2000) 1.09
Profiling studies in ovarian cancer: a review. Oncologist (2007) 1.09
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer (2001) 1.08
Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res (2004) 1.08
Tumor mRNA expression profiles predict responses to chemotherapy. J Clin Oncol (2007) 1.08
Intensity-based analysis of two-colour microarrays enables efficient and flexible hybridization designs. Nucleic Acids Res (2004) 1.08
Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer (2004) 1.07
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci (2006) 1.06
Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel. Cancer Res (2006) 1.02
Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene (2005) 1.00
Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol (2006) 0.98
Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. Int J Gynecol Cancer (2006) 0.95
c-Ets1 is a promising marker in epithelial ovarian cancer. Int J Mol Med (2002) 0.94
Induction of glomerular alkaline phosphatase after challenge with lipopolysaccharide. Int J Exp Pathol (2003) 0.93
Statistically designing microarrays and microarray experiments to enhance sensitivity and specificity. Brief Bioinform (2006) 0.91
Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci (2008) 0.88
Role of the transcription factor Ets-1 in cisplatin resistance. Mol Cancer Ther (2004) 0.88
cAMP response element-binding (CREB) signalling and ovarian surface epithelial cell survival. J Endocrinol (2006) 0.86
Molecular cloning, characterization, and chromosomal localization of FKBP23, a novel FK506-binding protein with Ca2+-binding ability. Genomics (1998) 0.86
A biological question and a balanced (orthogonal) design: the ingredients to efficiently analyze two-color microarrays with Confirmatory Factor Analysis. BMC Genomics (2006) 0.84
Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells. Int J Gynecol Cancer (2006) 0.79
New targets and non-cytotoxics in ovarian cancer. Ann Oncol (2006) 0.77
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Multiple common variants for celiac disease influencing immune gene expression. Nat Genet (2010) 6.90
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet (2011) 3.68
Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. PLoS Genet (2011) 3.65
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation (2006) 3.44
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med (2003) 3.15
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Metformin: taking away the candy for cancer? Eur J Cancer (2010) 2.68
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer (2012) 2.39
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and future. Hum Mutat (2012) 2.32
Unraveling the regulatory mechanisms underlying tissue-dependent genetic variation of gene expression. PLoS Genet (2012) 2.29
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability. Am J Hum Genet (2010) 2.12
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med (2009) 2.12
Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol (2008) 2.03
C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet (2008) 2.03
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res (2010) 2.03
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol (2005) 2.01
[Primary surgery by a gynecological oncologist improves the prognosis in patients with ovarian carcinoma]. Ned Tijdschr Geneeskd (2009) 1.97
TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev (2008) 1.94
Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res (2013) 1.87
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol (2010) 1.84
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med (2007) 1.79
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol (2006) 1.79
Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm (2009) 1.78
High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol (2003) 1.77
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry. Clin Chem (2007) 1.74
Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat (2012) 1.74
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet (2004) 1.66
The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat (2011) 1.65
Left ventricular outflow tract obstruction: should cardiac screening be offered to first-degree relatives? Heart (2011) 1.63
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005) 1.62
Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum Mutat (2012) 1.61
MixupMapper: correcting sample mix-ups in genome-wide datasets increases power to detect small genetic effects. Bioinformatics (2011) 1.60
Human disease-associated genetic variation impacts large intergenic non-coding RNA expression. PLoS Genet (2013) 1.59
The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association? Ann Surg Oncol (2006) 1.58
The insulin-like growth factor system and sarcomas. J Pathol (2009) 1.57
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2006) 1.57
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer (2006) 1.55
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol (2009) 1.53
TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res (2006) 1.52
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail (2012) 1.51
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene (2004) 1.50
Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002) 1.50
Homozygous nonsense mutations in KIAA1279 are associated with malformations of the central and enteric nervous systems. Am J Hum Genet (2005) 1.47
Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta (2009) 1.45
Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. Hum Mutat (2008) 1.44
Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.43
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest (2010) 1.43
RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev (2006) 1.41
Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept. Mol Imaging Biol (2011) 1.41
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
Clinical and genetic characterization of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy caused by a plakophilin-2 splice mutation. Cardiology (2012) 1.40
Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med (2007) 1.39
High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. Am Heart J (2007) 1.38
A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy. Hum Mutat (2009) 1.38
ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res (2005) 1.37
Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2003) 1.36
A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat (2006) 1.34
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol (2004) 1.31
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res (2003) 1.29